Development and validation of a humanized mouse psoriasis model to be applied for efficacy analysis of novel therapeutic compounds

Development and validation of a humanized mouse psoriasis model to be applied for efficacy analysis of novel therapeutic compounds - Development and validation of a pre-clinical psoriasis model

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON41218

Enrollment

Registered

2014-02-19

Start date

2014-04-07

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Flaking disease Psoriasis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Adult Psoriasis patients, m/f, with a mild to moderate form of psoriasis vulgaris, i.e. a maximal PASI score of 18 and a minimum BSA of 3%. Patients are allowed to use local corticosteroids or ointments to prevent dry skin (see Appendix 2).

Exclusion criteria

Exclusion criteria: Psoriasis patients have NOT received light therapy or another form of SYSTEMIC treatment (e.g. treatment with methotrexate, cyclosporin A or anti-TNF). Gender or age of the adult patients are no exclusion criteria (see Appendix 2).

Design outcomes

Primary

Measure	Time frame
After finalization of the validation study, the transplanted biopsies are isolated to study the psoriatic process via histological techniques. The primary read-out is epidermal thickness.	—

Secondary

Measure	Time frame
After finalization of the validation study, the transplanted biopsies are isolated to study the psoriatic process via histological techniques. The secundary read-out is proliferation and differentiation of cells in the skin. Moreover, the activation and differentiation status of immune cells will be determined in the blood of the donors.	—

Countries

Netherlands

Outcome results